Whitehawk (WHWK) CSO David Dornan Receives Equity Awards

What Happened

• David Dornan, Chief Scientific Officer of Whitehawk Therapeutics, was granted two equity awards on September 15, 2026: one award of 85,887 derivative shares and a second award of 85,887 derivative shares. Each grant is reported at $0.00 (no cash paid / reported value $0) and is a contingent equity award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-09-15; Transaction type: Award/Grant (code A); Price reported: $0.00.
• Award amounts: 85,887 shares (first grant) and 85,887 shares (second grant) — 171,774 shares in total.
• Vesting/conditions:
  • One award follows the plan in Footnote F1: 25% vests on the one‑year anniversary of the Vesting Commencement Date (Sept 15, 2026) and then 1/48th monthly thereafter, fully vesting after four years.
  • The other award is RSUs (Footnote F2 + F3): each RSU equals a contingent right to one share; 25% vests on each of the next four anniversaries beginning Sept 15, 2026.
  • Both awards are conditioned on Dornan’s continued service as a “Service Provider” under the company’s 2021 Equity Incentive Plan.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported and filed for the same date (2026-09-15) — appears timely; no late filing flag indicated.

Context

• These awards are service‑based grants (not purchases or sales) and vest over multiple years, so they do not represent an immediate market purchase or sale. RSUs convert to shares only when vested (per F2), and the option‑style award described in F1 requires continued service and a multi‑year vesting schedule. Such grants are common compensation tools for executives and are meant to align long‑term incentives rather than signal short‑term trading intent.